Cover Image
市場調查報告書

ChemoCentryx, Inc. : 產品平台分析

ChemoCentryx, Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 214147
出版日期 內容資訊 英文 56 Pages
訂單完成後即時交付
價格
Back to Top
ChemoCentryx, Inc. : 產品平台分析 ChemoCentryx, Inc. - Product Pipeline Review - 2016
出版日期: 2016年09月30日 內容資訊: 英文 56 Pages
簡介

ChemoCentryx, Inc. (ChemoCentryx) 這個生物製藥公司,正在從事治療自體免疫疾病和發炎,癌症等所用口服給藥劑的開發。

本報告提供ChemoCentryx, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃相關等資訊。

ChemoCentryx, Inc.的基本資料

  • ChemoCentryx, Inc.概要
  • 主要資訊
  • 企業資料

ChemoCentryx, Inc.:R&D概要

  • 主要的治療範圍

ChemoCentryx, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

ChemoCentryx, Inc.:開發中產品概況

  • 最後階段的開發中產品
    • 第Ⅲ階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第Ⅱ階段的產品/聯合治療模式
    • 第Ⅰ階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式
  • ChemoCentryx, Inc.:開發階段不明的開發中產品
  • 開發階段不明的產品/聯合治療模式

ChemoCentryx, Inc.:藥物簡介

  • vercirnon sodium
  • CCX-140
  • CCX-168
  • CCX-354
  • CCX-507
  • CCX-872
  • CCX-1378
  • CCX-1641
  • CCX-6239
  • CCX-650
  • CCX-721
  • CCX-771
  • 未公佈的症狀 CCR1 拮抗小分子
  • 乾癬 CCR6 拮抗小分子
  • 自體免疫疾病·腫瘤學·肝臟疾病 CXCR6 拮抗小分子
  • 腫瘤學·自體免疫疾病 CCR 及 CXCR 拮抗小分子
  • CCR2-3G
  • CCR9-3G
  • CCX-956

ChemoCentryx, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

ChemoCentryx, Inc.:最近的開發平台趨勢

ChemoCentryx, Inc.:暫停中的計劃

ChemoCentryx, Inc.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
  • CCX-832
  • vercirnon sodium

ChemoCentryx, Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08138CDB

Summary

Global Markets Direct's, 'ChemoCentryx, Inc. - Product Pipeline Review - 2016', provides an overview of the ChemoCentryx, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by ChemoCentryx, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of ChemoCentryx, Inc.
  • The report provides overview of ChemoCentryx, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses ChemoCentryx, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features ChemoCentryx, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate ChemoCentryx, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for ChemoCentryx, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding ChemoCentryx, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • ChemoCentryx, Inc. Snapshot
    • ChemoCentryx, Inc. Overview
    • Key Facts
  • ChemoCentryx, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • ChemoCentryx, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • ChemoCentryx, Inc. - Pipeline Products Glance
    • ChemoCentryx, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • ChemoCentryx, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • ChemoCentryx, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • ChemoCentryx, Inc. - Drug Profiles
    • CCR-23G - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCR-93G - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCX-140 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCX-168 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCX-354 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCX-507 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCX-6239 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCX-650 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCX-771 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCX-872 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCX-9588 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCX-991 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize CCR1 for Undisclosed Indication - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize CXCR6 for Autoimmune, Oncology and Liver Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Target C5aR for Undisclosed Indication - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize CCR and CXCR for Oncology and Autoimmune Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vercirnon sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • ChemoCentryx, Inc. - Pipeline Analysis
    • ChemoCentryx, Inc. - Pipeline Products by Target
    • ChemoCentryx, Inc. - Pipeline Products by Route of Administration
    • ChemoCentryx, Inc. - Pipeline Products by Molecule Type
    • ChemoCentryx, Inc. - Pipeline Products by Mechanism of Action
  • ChemoCentryx, Inc. - Dormant Projects
  • ChemoCentryx, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • CCX-832
      • vercirnon sodium
  • ChemoCentryx, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • ChemoCentryx, Inc., Key Facts
  • ChemoCentryx, Inc. - Pipeline by Indication, 2016
  • ChemoCentryx, Inc. - Pipeline by Stage of Development, 2016
  • ChemoCentryx, Inc. - Monotherapy Products in Pipeline, 2016
  • ChemoCentryx, Inc. - Phase III, 2016
  • ChemoCentryx, Inc. - Phase II, 2016
  • ChemoCentryx, Inc. - Phase I, 2016
  • ChemoCentryx, Inc. - Preclinical, 2016
  • ChemoCentryx, Inc. - Discovery, 2016
  • ChemoCentryx, Inc. - Pipeline by Target, 2016
  • ChemoCentryx, Inc. - Pipeline by Route of Administration, 2016
  • ChemoCentryx, Inc. - Pipeline by Molecule Type, 2016
  • ChemoCentryx, Inc. - Pipeline Products by Mechanism of Action, 2016
  • ChemoCentryx, Inc. - Dormant Developmental Projects,2016
  • ChemoCentryx, Inc. - Discontinued Pipeline Products, 2016
  • ChemoCentryx, Inc., Subsidiaries

List of Figures

  • ChemoCentryx, Inc. - Pipeline by Top 10 Indication, 2016
  • ChemoCentryx, Inc. - Pipeline by Stage of Development, 2016
  • ChemoCentryx, Inc. - Monotherapy Products in Pipeline, 2016
  • ChemoCentryx, Inc. - Pipeline by Top 10 Target, 2016
  • ChemoCentryx, Inc. - Pipeline by Route of Administration, 2016
  • ChemoCentryx, Inc. - Pipeline by Molecule Type, 2016
  • ChemoCentryx, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top